Therapy of small cell lung cancer with emphasis on oral topotecan

Abstract Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin pl...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2010-10, Vol.70 (1), p.7-13
Main Authors: Pirker, Robert, Berzinec, Peter, Brincat, Stephen, Kasan, Peter, Ostoros, Gyula, Pesek, Milos, Plāte, Signe, Purkalne, Gunta, Rooneem, Regina, Skřičková, Jana, Stanculeanu, Dana, Timcheva, Constanta, Tzekova, Valentina, Zakotnik, Branko, Zielinski, Christoph C, Zwitter, Matjaz
Format: Article
Language:English
Subjects:
Administration, Oral
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antineoplastic Agents - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Antiviral agents
Biological and medical sciences
Brain irradiation
Chemotherapy
Combined Modality Therapy
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - radiotherapy
Medical sciences
New drugs
Pharmacology. Drug treatments
Pneumology
Pulmonary/Respiratory
Second-line therapy
Small Cell Lung Carcinoma - drug therapy
Small Cell Lung Carcinoma - radiotherapy
Thoracic radiotherapy
Topoisomerase I Inhibitors - administration & dosage
Topotecan
Topotecan - administration & dosage
Tumors
Tumors of the respiratory system and mediastinum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin plus etoposide in a Japanese trial but failed to do so in two trials in Caucasians. Cisplatin plus topotecan had similar efficacy compared to cisplatin plus etoposide in patients with extensive disease. In the second-line setting, topotecan showed similar efficacy but better tolerability compared to cyclophosphamide, doxorubin plus vincristine. Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy. Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2010.05.020